How large is the non-muscle invasive bladder cancer market, and what is its growth trajectory?
The non-muscle invasive bladder cancer market size has grown strongly in recent years. It will grow from $3.46 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to growth in the aging population, growth in healthcare spending, growth in healthcare infrastructure, growth in telemedicine, and a rise in smoking rates.
The non-muscle invasive bladder cancer market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to rising adoption of targeted therapies, increasing focus on personalized medicine, growing investments in oncology research, growing demand for minimally invasive procedures, and rising incidence of chronic bladder. Major trends in the forecast period include technological advancements, precision medicine, artificial intelligence, telemedicine, and digital health tools.
Get Your Free Sample of The Global Non-Muscle Invasive Bladder Cancer Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20904&type=smp
What are the key forces behind the non-muscle invasive bladder cancer market’s growth in recent years?
The growing demand for minimally invasive procedures is expected to propel the growth of the non-muscle invasive bladder cancer market going forward. Minimally invasive procedures are surgical techniques that utilize small incisions and specialized instruments to perform operations with less tissue damage, resulting in reduced pain, shorter recovery times, and minimal scarring compared to traditional open surgery. The increasing focus on minimally invasive procedures is driven by factors such as reduced recovery time, improved patient outcomes, and the growing aging population, which collectively enhance patient safety, satisfaction, and efficiency in healthcare. Non-muscle invasive bladder cancer enables minimally invasive procedures by allowing for localized treatments such as transurethral resection and intravesical therapy, which target the tumor without the need for extensive surgical intervention. For instance, in August 2023, according to The Aesthetic Society, a US-based organization of plastic surgery and cosmetic medicine, Americans spent more than $11.8 billion on aesthetic procedures overall, up 2% from the previous year. Therefore, the growing demand for minimally invasive procedures is driving the growth of the non-muscle invasive bladder cancer market.
Impact Of Personalized Medicine On Patient Outcomes In Cancer Care
The growing focus on personalized medicine is expected to propel the growth of the non-muscle invasive bladder cancer market going forward. Personalized medicine involves customizing medical treatment based on an individual’s genetic profile, lifestyle, and environment for more effective outcomes. The growing focus on personalized medicine is driven by several factors, such as advancements in genomic research, improved diagnostic tools, and the growing demand for more targeted and effective treatments. Non-muscle invasive bladder cancer supports personalized medicine by enabling tailored treatment plans based on specific tumor characteristics, genetic markers, and individual patient profiles. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, this is driving the growth of the non-muscle invasive bladder cancer market.
What are the major segments of the non-muscle invasive bladder cancer market?
The non-muscle invasive bladder cancer market covered in this report is segmented –
1) By Stage: Carcinoma In Situ (CIS), T1 Stage, Ta Stage
2) By Treatment: Immunotherapy, Chemotherapy, Surgery, Intravesical Therapy, Others Treatments
3) By Tumor: Low-Grade Tumours, High-Grade Tumours
4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Carcinoma In Situ (CIS): High-Grade CIS, Low-Grade CIS
2) By T1 Stage: T1a Stage (Superficial Tumors), T1b Stage (Invasive Into Lamina Propria)
3) By Ta Stage: Low-Grade Ta Stage, High-Grade Ta Stage
Order your report now for swift delivery
Which companies dominate the non-muscle invasive bladder cancer market?
Major companies operating in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co. Inc., AstraZeneca plc, Moderna Inc., Astellas Pharma US Inc., Ferring Pharmaceuticals, EMD Serono Inc., Fidia Farmaceutici SpA, Genentech Inc., Aura Biosciences Inc., UroGen Pharma Ltd., Asieris Pharmaceuticals, Protara Therapeutics Inc., Hamlet Pharma AB, Istari Oncology Inc., Heat Biologics Inc., Telormedix SA, Viventia Bio Inc., Theralase Technologies Inc., Vaxiion Therapeutics Inc., ImmunityBio Inc., Altor BioScience Corporation, SURGE Therapeutics Inc.
Which key trends are expected to influence the non-muscle invasive bladder cancer market in the coming years?
Major companies operating in the non-muscle invasive bladder cancer market are focusing on developing innovative products, such as immunotherapy, to improve treatment options and outcomes for patients. Immunotherapy involves harnessing the body’s immune system to detect and combat cancer cells by boosting or activating immune responses. For instance, in March 2024, ImmunityBio Inc., a US-based biotechnology company, received approval from the Food and Drug Administration (FDA) for ANKTIVA (N-803) in the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) featuring carcinoma in situ (CIS), with or without papillary tumors. This approval is based on promising clinical trial results, which show that ANKTIVA, when used in combination with Bacillus Calmette-Guérin (BCG), offers a viable treatment option for patients who have not responded to standard BCG therapy. ANKTIVA is a pioneering IL-15 agonist immunotherapy that works by enhancing the immune system, specifically stimulating natural killer (NK) cells and CD8+ killer T cells to target and destroy cancer cells.
What are the key regional dynamics of the non-muscle invasive bladder cancer market, and which region leads in market share?
North America was the largest region in the non-muscle invasive bladder cancer market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-muscle invasive bladder cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Non-Muscle Invasive Bladder Cancer Market Report 2025 Offer?
The non-muscle invasive bladder cancer market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Non-muscle invasive bladder cancer (NMIBC) refers to a type of bladder cancer that is confined to the inner layers of the bladder wall and has not spread to the muscle layer. It is typically diagnosed at an early stage and can often be treated effectively with methods such as transurethral resection, intravesical therapy, or close surveillance.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20904
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
